Iranian Red Crescent Medical Journal

Published by: Kowsar

Utility of Myelin Basic Protein as an Early Prognostic Biomarker in Multiple Sclerosis

Samiie Pouragahi 1 , 3 , 7 , Marjan Nassiri-Asl 2 , * , Mohammad Ali Sahraian 3 , Mehdi Sadeghi 4 , Abdolali Banki 5 , Zahra Zamanzadeh 6 , Mitra Ataei 6 and Mohammad Hossein Sanati 7 , *
Authors Information
1 Department of Molecular Medicine, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran
2 Cellular and Molecular Research Center, Department of Pharmacology, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran
3 Multiple Sclerosis Research Center, Sina Hospital, Department of Neurology, Tehran University of Medical Sciences, Tehran, Iran
4 Department of Bioinformatics, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran
5 Department of Neurology, Baqiyatallah University of Medical Sciences, Baqiyatallah Hospital, Tehran, Iran
6 National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran
7 Department of Molecular Genetics, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran
Corresponding Authors:
Article information
  • Iranian Red Crescent Medical Journal: March 01, 2017, 19 (3); e41619
  • Published Online: October 18, 2016
  • Article Type: Research Article
  • Received: August 19, 2016
  • Revised: September 11, 2016
  • Accepted: October 10, 2016
  • DOI: 10.5812/ircmj.41619

To Cite: Pouragahi S, Nassiri-Asl M, Sahraian M A, Sadeghi M, Banki A, et al. Utility of Myelin Basic Protein as an Early Prognostic Biomarker in Multiple Sclerosis, Iran Red Crescent Med J. 2017 ; 19(3):e41619. doi: 10.5812/ircmj.41619.

Abstract
Copyright © 2016, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Paap BK, Hecker M, Koczan D, Zettl UK. Molecular biomarkers in multiple sclerosis. J Clin Cell Immunol. 2013; 2013
  • 2. Harris VK, Sadiq SA. Biomarkers of therapeutic response in multiple sclerosis: current status. Mol Diagn Ther. 2014; 18(6): 605-17[DOI][PubMed]
  • 3. Cusick MF, Libbey JE, Fujinami RS. Multiple sclerosis: autoimmunity and viruses. Curr Opin Rheumatol. 2013; 25(4): 496-501[DOI][PubMed]
  • 4. Ljubisavljevic S, Stojanovic I, Pavlovic D, Milojkovic M, Sokolovic D, Stevanovic I, et al. Suppression of the lipid peroxidation process in the CNS reduces neurological expression of experimentally induced autoimmune encephalomyelitis. Folia Neuropathol. 2013; 51(1): 51-7
  • 5. Bamm V, Lanthier DK, Stephenson EL, Smith G, Harauz G. In vitro study of the direct effect of extracellular hemoglobin on myelin components. Bba-Mol Basis Dis. 2015; 1852(1): 92-103
  • 6. Harauz G, Boggs JM. Myelin management by the 18.5-kDa and 21.5-kDa classic myelin basic protein isoforms. J Neurochem. 2013; 125(3): 334-61[DOI][PubMed]
  • 7. Ontaneda D, Hyland M, Cohen JA. Multiple sclerosis: new insights in pathogenesis and novel therapeutics. Annu Rev Med. 2012; 63: 389-404[DOI][PubMed]
  • 8. Belogurov AJ, Kudriaeva A, Kuzina E, Smirnov I, Bobik T, Ponomarenko N, et al. Multiple sclerosis autoantigen myelin basic protein escapes control by ubiquitination during proteasomal degradation. J Biol Chem. 2014; 289(25): 17758-66[DOI][PubMed]
  • 9. Mayer MC, Meinl E. Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more. Ther Adv Neurol Disord. 2012; 5(3): 147-59[DOI][PubMed]
  • 10. Medveczky P, Antal J, Patthy A, Kekesi K, Juhasz G, Szilagyi L, et al. Myelin basic protein, an autoantigen in multiple sclerosis, is selectively processed by human trypsin 4. FEBS Lett. 2006; 580(2): 545-52[DOI][PubMed]
  • 11. Aggarwal S, Yurlova L, Simons M. Central nervous system myelin: structure, synthesis and assembly. Trends Cell Biol. 2011; 21(10): 585-93[DOI][PubMed]
  • 12. Moscarello MA. Myelin basic protein, the executive molecule of the myelin membrane. 1997;
  • 13. Simons K, Ehehalt R. Cholesterol, lipid rafts, and disease. J Clin Invest. 2002; 110(5): 597-603[DOI][PubMed]
  • 14. Vassall KA, Bessonov K, De Avila M, Polverini E, Harauz G. The effects of threonine phosphorylation on the stability and dynamics of the central molecular switch region of 18.5-kDa myelin basic protein. PLoS One. 2013; 8(7): 68175[DOI][PubMed]
  • 15. Katsavos S, Anagnostouli M. Biomarkers in Multiple Sclerosis: An Up-to-Date Overview. Mult Scler Int. 2013; 2013: 340508[DOI][PubMed]
  • 16. Damal K, Stoker E, Foley JF. Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action. Biologics. 2013; 7: 247-58[DOI][PubMed]
  • 17. Lauer K. Notes on the epidemiology of multiple sclerosis, with special reference to dietary habits. Int J Mol Sci. 2014; 15(3): 3533-45[DOI][PubMed]
  • 18. Heydarpour P, Mohammad K, Yekaninejad MS, Elhami SR, Khoshkish S, Sahraian MA. Multiple sclerosis in Tehran, Iran: a joinpoint trend analysis. Mult Scler. 2014; 20(4): 512[DOI][PubMed]
  • 19. Sahraian MA, Khorramnia S, Ebrahim MM, Moinfar Z, Lotfi J, Pakdaman H. Multiple sclerosis in Iran: a demographic study of 8,000 patients and changes over time. Eur Neurol. 2010; 64(6): 331-6[DOI][PubMed]
  • 20. Etemadifar M, Sajjadi S, Nasr Z, Firoozeei TS, Abtahi SH, Akbari M, et al. Epidemiology of multiple sclerosis in Iran: a systematic review. Eur Neurol. 2013; 70(5-6): 356-63[DOI][PubMed]
  • 21. Cygan NK, Scheinost C, Butters TD, Wentworth J P. Adduction of cholesterol 5, 6-secosterol aldehyde to membrane-bound myelin basic protein exposes an immunodominant epitope. Biochem. 2011; 50(12): 2092-100
  • 22. Musse AA, Harauz G. Molecular “negativity” may underlie multiple sclerosis: role of the myelin basic protein family in the pathogenesis of MS. International Rev Neurobiol. 2007; 79: 149-72
  • 23. Harris VK, Sadiq SA. Disease biomarkers in multiple sclerosis. Mol Diagnos Ther. 2009; 13(4): 225-44
  • 24. Hogeboom C. Peptide motif analysis predicts lymphocytic choriomeningitis virus as trigger for multiple sclerosis. Mol Immunol. 2015; 67(2 Pt B): 625-35[DOI][PubMed]
  • 25. Hughes LE, Smith PA, Bonell S, Natt RS, Wilson C, Rashid T, et al. Cross-reactivity between related sequences found in Acinetobacter sp., Pseudomonas aeruginosa, myelin basic protein and myelin oligodendrocyte glycoprotein in multiple sclerosis. J Neuroimmunol. 2003; 144(1): 105-15
  • 26. Mameli G, Cossu D, Cocco E, Masala S, Frau J, Marrosu MG, et al. Epstein–Barr virus and Mycobacterium avium subsp. paratuberculosis peptides are cross recognized by anti-myelin basic protein antibodies in multiple sclerosis patients. J Neuroimmunol. 2014; 270(1): 51-5
  • 27. Zheng MM, Zhang XH. Cross-reactivity between human cytomegalovirus peptide 981-1003 and myelin oligodendroglia glycoprotein peptide 35-55 in experimental autoimmune encephalomyelitis in Lewis rats. Biochem Biophys Res Commun. 2014; 443(3): 1118-23[DOI][PubMed]
  • 28. Parkhomenko TA, Legostaeva GA, Doronin BM, Buneva VN, Nevinsky GA. IgGs containing light chains of the λ and κ type and of all subclasses (IgG1‐IgG4) from sera of patients with multiple sclerosis hydrolyze DNA. J Mol Recognit. 2010; 23(5): 486-94
  • 29. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50(1): 121-7[PubMed]
  • 30. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005; 58(6): 840-6[DOI][PubMed]
  • 31. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011; 69(2): 292-302[DOI][PubMed]
  • 32. Kou S, Zheng Q, Wang Y, Zhao H, Zhang Q, Li M, et al. Zuo-Gui and You-Gui pills, two traditional Chinese herbal formulas, downregulated the expression of NogoA, NgR, and RhoA in rats with experimental autoimmune encephalomyelitis. J Ethnopharmacol. 2014; 158: 102-12
  • 33. Koncarevic S, Lobner C, Kuhn K, Prinz T, Pike I, Zucht HD. In-depth profiling of the peripheral blood mononuclear cells proteome for clinical blood proteomics. Int J Proteom. 2014; 2014
  • 34. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002; 30(9): 36
  • 35. Doronin VB, Parkhomenko TA, Castellazzi M, Padroni M, Pastore M, Buneva VN, et al. Comparison of antibodies hydrolyzing myelin basic protein from the cerebrospinal fluid and serum of patients with multiple sclerosis. PLoS One. 2014; 9(9): 107807[DOI][PubMed]
  • 36. Lomakin YA, Zakharova MY, Stepanov AV, Dronina MA, Smirnov IV, Bobik TV, et al. Heavy–light chain interrelations of MS-associated immunoglobulins probed by deep sequencing and rational variation. Molecular Immunol. 2014; 62(2): 305-14
  • 37. Namekata K, Kimura A, Harada C, Yoshida H, Matsumoto Y, Harada T. Dock3 protects myelin in the cuprizone model for demyelination. Cell Death Dis. 2014; 5(8): 1395
  • 38. Cusick MF, Libbey JE, Fujinami RS. Molecular mimicry as a mechanism of autoimmune disease. Clin Rev Allergy Immunol. 2012; 42(1): 102-11[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments